Pfizer, BioNTech’s Covid-19 vaccine candidate meets all primary efficacy endpoints in phase 3 study

This article was originally published here

The data analysis showed a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection (primary infection), as well as in participants with and without prior SARS-CoV-2

The post Pfizer, BioNTech’s Covid-19 vaccine candidate meets all primary efficacy endpoints in phase 3 study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply